All In Biotech

Drug Trial Radar · NCT06738836

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EDG-7500 Following Single-Dose Oral Administration

Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Dec 3, 2024

Primary completion

Jan 17, 2025

Study completion Jan 17, 2025

Sponsor

Lead sponsor
Edgewise Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to: 1. Assess the mass balance (i.e., the cumulative elimination of 14C-related material in urine and feces, compared to the administered amount of radioactive isotope) of \[14C\]-EDG-7500 following a single oral dose of EDG-7500 containing a radioactive tracer, in healthy, adult male subjects. 2. Characterize the pharmacokinetics of EDG-7500 in plasma and of 14C-related material in whole blood, plasma, urine and feces following a single oral dose of EDG-7500 containing a radioactive tracer, in healthy, adult male subjects.

Conditions

  • Healthy Volunteer

Interventions

  • [14C]-EDG-7500Drug

    Oral liquid suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mass BalanceTime frame: From Day -1 through study completion (up to 19 days)
  2. Pharmacokinetics of EDG-7500 in plasma and 14C total radioactivity in plasma and whole blood as measured by CmaxTime frame: From Day 1 to study completion (up to 18 days)
  3. Pharmacokinetics of EDG-7500 in plasma and 14C total radioactivity in plasma and whole blood as measured by TmaxTime frame: From Day 1 to study completion (up to 18 days)
  4. Pharmacokinetics of EDG-7500 in plasma and 14C total radioactivity in plasma and whole blood as measured by T1/2Time frame: From Day 1 to study completion (up to 18 days)
  5. Pharmacokinetics of EDG-7500 in plasma and 14C total radioactivity in plasma and whole blood as measured by AUC0-infTime frame: From Day 1 to study completion (up to 18 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron Clinical Pharmacology Center, Inc.

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.